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Abstract
Coronaviruses commonly cause mild infections, but recently severe acute respiratory syndrome-coronavirus (SARS-
CoV)-2 caused a pandemic of coronavirus disease 2019 (COVID-19). A total of 3,181,642 cases were confirmed 
globally. Gastrointestinal tract may be involved in COVID-19 due to the presence of angiotensin converting enzyme-2 
(ACE2) and transmembrane protease serine 2 (TMPRSS2) in small intestine and colon which are mandatory for 
SARS-CoV-2 invasion. A proportion of patients with COVID-19 had gastrointestinal manifestation without respiratory 
symptoms. Viable virus can also be isolated from feces of patients. Fecal-oral transmission should be considered in 
controlling disease spreading. Fecal examination may also be considered to diagnose COVID-19, especially in areas 
with limited personal protective equipment.
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Introduction
Coronavirus is enveloped non-segmented 
positive-sense RNA virus from Coronaviridae family 
and Nidovirales order. The virus is commonly found in 
several mammals, including bats [1]. Most of coronavirus 
infections are mild, but there were several epidemics due to 
the infection such as severe acute respiratory syndrome-
coronavirus (SARS-CoV) and Middle-East respiratory 
syndrome-coronavirus (MERS-CoV). Both epidemics 
had high mortality rates with MERS-CoV as the highest 
(37%) [2]. Recently, an outbreak of coronavirus disease 
2019 (COVID-19) due to SARS-CoV-2 occurred at the 
end of 2019. It started in Wuhan, Hubei, China, and now, 
it spreads globally, affecting 199 countries [2], [3], [4], [5]. 
On March 11, 2020, the World Health Organization 
(WHO) declared it as a pandemic [1].
Epidemiology
On May 1st 2020, there was a total of 3,181,642 
confirmed cases of COVID-19 worldwide with 224,301 
death cases. Europe was the region with highest 
prevalence rate (1,461,404 cases) while the USA was 
the highest prevalence country with 1,035,353 cases [6]. 
Most of patients were male with underlying diseases 
such as diabetes, hypertension, and cardiovascular 
diseases [2] [7] [8]. The median age of infected patients 
was 49.0 years [2]. Other study stated that mean age 
of the patients was 46.14 years and 10.8% of them had 
pre-existing liver disease [9]. The most common death 
leading complication was acute respiratory distress 
syndrome. The death rate reported from a study by 
Huang et al. was 15% [2].
Pathophysiology
The virus mainly infects respiratory epithelial 
cells and spreads from human to human through 
respiratory tract [7]. Gastrointestinal tract is also affected 
in COVID-19, similar with SARS-CoV and MERS-CoV, 
but the manifestations are uncommon [1], [3], [10]. Lin 
et al. found that SARS-CoV-2 could be detected in 
esophagus, stomach, duodenum, and rectum. The virus 
was also present in 52.4% of patients’ feces [11]. SARS-
CoV-2 needs angiotensin-converting enzyme-2 (ACE2) 
and transmembrane protease serine 2 (TMPRSS2) to 
enter host cells [1], [2], [3], [7], [8], [12], [13]. Both are 
highly expressed in small intestine and colon, but not 
in esophagus. This raises probability that the virus can 
invade through digestive tract. The invasion causes the 
development of gastrointestinal manifestations [3], [7]. 
After binding with ACE2, the virus enters host cell. 
Viral RNA then integrates into host cell DNA. This 
process initiates viral protein synthesis and assembly 
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of new viruses. This new viruses may invade other 
cells or released into body fluid in respiratory and 
gastrointestinal tract [7]. As the role of ACE2 is to 
mediate inflammation, the infection causes damage in 
ACE2 receptor, increases in inflammation, damages in 
mucosa, and triggers diarrhea [12], [14]. In addition, viral 
invasion causes inflammatory response and imbalance 
of intestinal microorganism which further damages the 
digestive system and manifested as gastrointestinal 
symptoms [8], [13]. The effect of gut–lung axis is also 
suspected to play an important role in the interaction 
between respiratory and gastrointestinal manifestations 
through the common mucosal immune system [8]. 
A study by Xiao et al. proved that gastrointestinal 
epithelium of patients with COVID-19 suffered from 
damage based on endoscopy findings. The damage 
was observed in esophagus, stomach, duodenum, 
and rectum. Viral RNA was found in esophageal 
mucosa but not viral nucleocapsid, indicating that 
the viral invasion was absent in esophagus due to 
the absence of ACE2 [7]. ACE2 is also detected in 
hepatocytes and cholangiocytes so it is possible that 
liver is involved with SARS-CoV-2 infection. However, 
the effect of medications, including antibiotic and 
experimental antiviral, must also be in concern as 
the aggravating factors of liver damage along with 
other underlying comorbidities. However, the binding 
efficiency is thought to be stronger for SARS-CoV-2 
compared to other coronavirus. A literature stated that 
binding affinity of SARS-CoV-2 is 73% stronger than 
SARS-CoV. This explains the high transmission rate of 
SARS-CoV-2 [12] [13].
Clinical manifestations
Classical manifestations of COVID-19 are 
fever, cough, dyspnea, and myalgia which indicate 
droplet as the main mode of transmission of the 
disease [2], [3], [5], [8],  10], [13]. In MERS-CoV or 
SARS-CoV infections, gastrointestinal manifestations 
were found in 20%–25% of patients [2], [10], [12]. 
Cheung et al. reported a cumulative prevalence of 
gastrointestinal manifestation in COVID-19 patients as 
much as 17.6% while Pan et al. reported a higher rate 
(20.5%) [1], [8]. Diarrhea was found in 1–3.8% of patients 
with COVID-19 while nausea and vomiting were found 
in 10.1% and 3.6% of patients, respectively [3]. Other 
study reported that anorexia was the most common 
gastrointestinal manifestation (26.8%) followed by 
diarrhea (12.5%) and nausea/vomiting (10.2%) [1]. In 
a study by Pan et al., anorexia was the most common 
gastrointestinal symptom (78.6%), followed by diarrhea 
(34%), vomiting (3.9%), and abdominal pain (1.9%) [8].
Jin et al. reported that gastrointestinal 
manifestations were found in 11.4% of patients with 
COVID-19 and 28% of patients with gastrointestinal 
manifestations did not have respiratory symptoms. 
Furthermore, they had more severe disease 
course compared to those without gastrointestinal 
manifestations [9]. Another study reported a higher 
rate of gastrointestinal manifestations in COVID-19 
patients. A total of 61.1% of patients had gastrointestinal 
manifestations which consisted of diarrhea (24.2%), 
nausea (17.9%), vomiting (42.2%), and impaired liver 
function (32.6%) [11]. Various degrees of liver damage 
had been reported in COVID-19 patients. Total bilirubin 
level raised in 10% of patients while ALT level rose in 
16%–35% of patients. Elevated AST was observed 
in 21% of patients and alkaline phosphatase was 
generally normal [12].
Auxiliary examinations
Real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR) of nasopharyngeal swab is 
used to confirm the diagnosis of COVID-19 [4], [5]. 
Other specimens also showed positive result with 
bronchoalveolar lavage fluid held the highest positive 
rate (93%), followed by sputum (72%), nasal swabs 
(63%), fibrobronchoscope brush biopsy (46%), 
pharyngeal swab (32%), feces (29%), and blood 
(1%) [4]. A meta-analysis reported that the prevalence 
of positive stool viral RNA was 48.1% [1]. The accuracy 
of SARS-CoV-2 detection from feces is comparable 
with nasopharyngeal swab. It can be suggested that 
the diagnosis of COVID-19 can be performed from 
fecal specimen, particularly in areas with limited 
personal protective equipment [5], [15]. From chest 
computed tomography, one can find ground-glass 
opacity [2], [5], while X-rays showed bilateral lung 
involvement in 98% of patients. From laboratory 
examination, 45% had white blood cell count between 
4000 and 10,000/mL, 69% had procalcitonin level 
of <0.1 ng/mL, and more than a half patients had 
lymphopenia. Critical patients showed elevated pro-
inflammatory cytokines, leading to a condition called 
cytokine storm [2]. The virus might be found in feces 
from day 1 to 12 of infection [7]. The potential of fecal-
oral transmission is present since SARS-CoV-2 is still 
detected in feces even after the virus has been cleared 
from respiratory tract [1], [3], [7], [13]. The presence of 
viable virus in feces makes it possible for the disease 
to spread through stool contaminated hand, food, and 
water. It is in concordance with the viability of virus 
in several environments [5], [12], [15]. The virus was 
still found in feces for a mean of 27.9 days after first 
symptom onset compared to 16.7 days in respiratory 
samples [15]. However, the presence of virus in feces 
was not associated with gastrointestinal manifestations, 
disease severity, and antiviral treatment [4], [5], [15]. 
Prevention of fecal-oral transmission should be taken 
into consideration to prevent further spreading of the 
disease [7], [10].
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Conclusion
COVID-19 is now a pandemic with increasing 
prevalence and mortality rates. The presence of ACE2 
and TMPRSS2 in gastrointestinal tract makes it possible 
for SARS-CoV-2 to invade through gastrointestinal 
tract and elicits manifestations. Anorexia and diarrhea 
are the most common gastrointestinal tract in COVID-
19 patients. Viable virus is also detected in feces 
of patients even though it has been cleared from 
respiratory tract. Fecal examination can be a candidate 
of diagnostic testing, especially in area with limited 
personal protective equipment. Further, consideration 
is mandatory regarding fecal-oral transmission of 
COVID-19.
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